Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

25.19 +0.15 (+0.60%)

Official Closing Price Updated: 7:00 PM EST, Dec 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Does This Acquisition Make Pfizer Stock a Great Buy? ↗

September 25, 2025

There's an opportunity to get in on the weight-loss drug craze at a reasonable price.

Via The Motley Fool

Topics Death Intellectual Property

Pfizer Tries To Fatten Its Profits With Weight Loss Drugs ↗

September 25, 2025

Pfizer needs to fortify its future revenues.

Via Talk Markets

Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025

September 25, 2025

From Pfizer Inc.

Via Business Wire

3 Top Dividend Stocks to Buy and Hold Forever ↗

September 25, 2025

These blue chip dividend stocks offer both income and growth potential.

Via The Motley Fool

Topics Intellectual Property

Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. ↗

September 25, 2025

Investors once speculated that Pfizer might consider acquiring Viking.

Via The Motley Fool

Healthcare Sector Grapples with 5% Slump in 2025: A Deep Dive into Market Underperformance

September 24, 2025

The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

What's Driving the Market Sentiment Around Pfizer? ↗

September 24, 2025

Via Benzinga

Why Cidara Therapeutics, Already Up 173% This Year, Just Hit A Five-Year High ↗

September 24, 2025

The company is accelerating plans to run Phase 3 testing of its non-vaccine flu prevention drug by six months.

Via Investor's Business Daily

Topics Intellectual Property

The Smartest Dividend Stock to Buy With $1,000 Right Now ↗

September 24, 2025

Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.

Via The Motley Fool

Topics Intellectual Property

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

September 24, 2025

Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.

Via The Motley Fool

Topics Intellectual Property

Where Will Pfizer Be in 5 Years? ↗

September 24, 2025

The pharma giant may be heading for a new era of growth.

Via The Motley Fool

Topics Intellectual Property

Time To Buy Pfizer Or Metsera Stock? ↗

September 24, 2025

Making a major move in the obesity drug market, Pfizer announced on Monday that it plans to acquire biotechnology firm Metsera by the end of the year for $4.9 billion or $47.50 a share.

Via Talk Markets

STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy

September 23, 2025

STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights...

Via MarketMinute

Topics Intellectual Property

Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

September 23, 2025

From Pfizer Inc.

Via Business Wire

The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now ↗

September 23, 2025

This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety?

Via The Motley Fool

3 High-Yielding Dividend Stocks to Buy and Hold for the Long Haul -- Including United Parcel Service (UPS) and Pfizer ↗

September 23, 2025

Each of these dividend payers sports a fat yield of more than 6.5%.

Via The Motley Fool

What's Pfizer Getting in Its $7.3 Billion Metsera Buyout? ↗

September 23, 2025

Pfizer's plan to enter the booming obesity market took an expensive new turn.

Via The Motley Fool

Prediction: Warren Buffett Is Retiring in 100 Days, and 3 Big Changes Are Coming to Berkshire Hathaway When He Does ↗

September 23, 2025

The post-Warren Buffett era for Berkshire Hathaway will look quite different.

Via The Motley Fool

Nvidia’s $100B Bet in OpenAI Pushes Wall Street to Fresh Records ↗

September 23, 2025

Tech did the heavy lifting as Nvidia and Apple dragged indexes over the finish line; gold hit yet another all-time high while oil sagged. The Fed chorus grew louder and more discordant.

Via Chartmill

Topics Economy

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ ↗

September 22, 2025

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

Via Stocktwits

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel' ↗

September 22, 2025

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current...

Via Benzinga

Topics Government

Why BioNTech Stock Bumped Higher Today ↗

September 22, 2025

Investors were cheered by two pieces of good news concerning the biotech's most famous product.

Via The Motley Fool

Curious about the most active S&P500 stocks in today's session? ↗

September 22, 2025

Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest...

Via Chartmill

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Via MarketMinute

Topics Economy Intellectual Property

MTSR Shares Jump After Pfizer Merger Agreement ↗

September 22, 2025

Metsera stock skyrocketed 62% as Pfizer struck a $4.9 billion acquisition agreement focused on obesity therapies.

Via Talk Markets

Why Pfizer Stock Just Popped ↗

September 22, 2025

Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's.

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)

September 22, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Gold Gains Over 1%; Quantum Computing Shares Plunge ↗

September 22, 2025

Via Benzinga

IBD 50's Tempus AI Hits Record High On Yet Another FDA Clearance ↗

September 22, 2025

The company is focusing on RNA sequencing as a means of assisting with drug development.

Via Investor's Business Daily

Topics Artificial Intelligence Intellectual Property

< Previous 1 2

...

18 19 20 21 22 23 24 25 26

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Pfizer (NY:PFE)

All News about Pfizer

Starting at $3.75/week.

Subscribe Today